Explore the Site

  • Latest News
  • AusBiotech
  • Events
  • About
  • Contact
  • Subscribe
  • Search

Follow Us

  • LinkedIn
  • Twitter
  • Instagram
BiotechDispatch Menu
November 18, 2026
  • Subscribe
  • Login
  • Latest News
  • AusBiotech
  • Events
  • About
  • Contact
  • Subscribe
  • Search

Sign In

  • Forgot password?
  • AusBiotech

    AusBiotech opens call for sessions for Brisbane's 2027 'Biggest Week in Biotech'

    November 17, 2026
  • Latest News

    Neurizon moves first HEALEY ALS participant into NUZ-001 extension ahead of 2027 readout

    November 17, 2026
  • Latest News

    Racura bridges new bisantrene formulation to earlier AML trial results

    November 17, 2026
  • Latest News Radiopharm brain metastases imaging agent closely matches MRI in interim Phase 2b data November 17, 2026
    Radiopharm Theranostics has reported interim results from a Phase 2b study of its imaging agent RAD101 in patients with suspected recurrent brain metastases after radiotherapy. The PET scans agreed with contrast-enhanced MRI in 93.5 per cent of patients.
  • BCAL widens breast cancer research beyond lipids as its science goes through peer review November 17, 2026
    BCAL Diagnostics has received ethics approval to take its breast cancer research beyond lipids. The company is also building the scientific record behind its blood test, with a paper published in a Nature Portfolio journal and a second now in revision.
  • Latest News Cartherics takes ovarian cancer cell therapy to London as first human trial nears November 11, 2026
    Melbourne biotechnology company Cartherics will use London Life Sciences Week to seek international partners, collaborators, and investors as its lead ovarian cancer therapy moves toward its first human trial.
  • Latest News Brandon Capital opens its Melbourne office doors to biotech tenants November 11, 2026
    Brandon Capital is inviting biotechnology, healthcare and life sciences businesses to take up office space alongside it at 31 Queen Street in the Melbourne CBD, where the venture investor has its Melbourne base on Level 9.
  • Celairis signs first major licensing deal with Ocugen's gene therapy for retinitis pigmentosa November 12, 2026
    Celairis Therapeutics has secured exclusive rights to commercialise Ocugen's investigational gene therapy for retinitis pigmentosa in Australia, New Zealand and the member states of the Association of Southeast Asian Nations.
  • Latest News Immutep's efti combination shows early survival signal in soft tissue sarcoma November 11, 2026
    Immutep has released the first survival data from EFTISARC NEO, a Phase II trial of its immunotherapy eftilagimod alfa in patients with soft tissue sarcoma that can be surgically removed. The results will be presented at the Connective Tissue Oncology Society annual meeting in Seoul later this month.
  • Latest News Syntara pauses scar study recruitment after skin irritation reports November 11, 2026
    Syntara has paused recruitment in its Phase 1b study of SNT-9465 after some participants reported mild to moderate skin irritation from the topical scar treatment.
  • Miro Sciences clears TGA manufacturing inspection ahead of Crohn's trial November 12, 2026
    The Therapeutic Goods Administration has completed its inspection of Q-Gen Cell Therapeutics, the Brisbane contract manufacturer that will make Miro Sciences' StemSmart stem cell product for a planned Phase 2 trial in refractory Crohn's disease.
  • Latest News NuNerve launches 75-patient Phase 2 MND trial of NUN-004 November 10, 2026
    NuNerve is taking its lead motor neurone disease therapy into a national Phase 2 trial after early signs of disease stabilisation and functional improvement in its first human study.
  • Latest News CLINUVEL bets its cash reserves on long acting injectables and a possible US listing November 9, 2026
    CLINUVEL managing director Philippe Wolgen has rejected calls from some shareholders for a share buyback. At the company's annual general meeting in Melbourne, he said the board would keep investing cash in research and a planned business transformation.
  • Latest News AVITA Medical raises guidance as Medicare locks in RECELL payment codes November 9, 2026
    AVITA Medical has raised its full-year revenue guidance and removed the going concern qualification from its accounts after a third quarter in which revenue grew 53 per cent on the same period last year.
  • Latest News Nexsen targets 2027 FDA filing for bedside kidney injury test November 9, 2026
    Nexsen says it aims to file its RenalSure bedside test for acute kidney injury with the US Food and Drug Administration in mid-2027. It has also started a feasibility study with Austrian company GENSPEED Biotech to evaluate a second, complementary test for the condition.
  • Tetratherix moves to new royalty arrangement with the University of Sydney November 10, 2026
    Tetratherix has reworked its royalty arrangements with the University of Sydney, replacing a layered set of payment obligations with a single flat royalty that the company says will strengthen its margins as its first products approach market.
  • Latest News First child dosed in Neurotech's Phase 3 cannabis trial for autism October 28, 2026
    The Melbourne company dosed the first patient in its Beyond Harmony study of NTI164 on 21 September. All six sites across Victoria, Queensland, New South Wales, Tasmania and Western Australia are now open.
  • Neuren lifts income outlook as German launch delivers milestone payment November 5, 2026
    Neuren's chief executive, Jon Pilcher, said the result positioned the company well beyond its home market. "The Neuren team is excited about the impressive performance of DAYBUE in Q3 2026 and an outlook that continues to strengthen."
  • Radiopharm secures FDA backing for a single pivotal trial of brain metastases imaging agent November 4, 2026
    Radiopharm Theranostics has reached agreement with the US Food and Drug Administration on the design of a single pivotal Phase 3 trial for RAD101, its imaging agent for brain metastases.
  • Latest News Miro Sciences maps path to Phase 2 trial of stem cell therapy for severe Crohn's disease November 5, 2026
    Miro Sciences, formerly NeuroScientific Biopharmaceuticals, has announced that it plans to start a randomised Phase 2 trial of its StemSmart cell therapy for people with severe Crohn's disease who have failed existing treatments. 
  • Latest News Island Pharmaceuticals moves closer to Marburg dosing as primate surgeries begin November 4, 2026
    Island Pharmaceuticals has started surgical preparations on the 22 nonhuman primates that will take part in its Galidesivir dose optimisation study for Marburg virus disease.

Most Read

  • AusBiotech opens call for sessions for Brisbane's 2027 'Biggest Week in Biotech'

    November 17, 2026 - AusBiotech
  • Neurizon moves first HEALEY ALS participant into NUZ-001 extension ahead of 2027 readout

    November 17, 2026 - Latest News
  • Racura bridges new bisantrene formulation to earlier AML trial results

    November 17, 2026 - Latest News
  • Radiopharm brain metastases imaging agent closely matches MRI in interim Phase 2b data

    November 17, 2026 - Latest News
  • BCAL widens breast cancer research beyond lipids as its science goes through peer review

    November 17, 2026

Follow Us

  • LinkedIn
  • Twitter
  • Instagram

New Stories

  • BCAL widens breast cancer research beyond lipids as its science goes through peer review

    November 17, 2026 -
  • AusBiotech opens call for sessions for Brisbane's 2027 'Biggest Week in Biotech'

    November 17, 2026 - - AusBiotech
  • Racura bridges new bisantrene formulation to earlier AML trial results

    November 17, 2026 - - Latest News
  • Radiopharm brain metastases imaging agent closely matches MRI in interim Phase 2b data

    November 17, 2026 - - Latest News
  • Neurizon moves first HEALEY ALS participant into NUZ-001 extension ahead of 2027 readout

    November 17, 2026 - - Latest News
  • Celairis signs first major licensing deal with Ocugen's gene therapy for retinitis pigmentosa

    November 12, 2026 -
  • Miro Sciences clears TGA manufacturing inspection ahead of Crohn's trial

    November 12, 2026 -
  • About Us
  • Contact Us
  • Privacy Policy
  • Subscribe
  • Powered by Newsroom

©2026 DailyDispatch Pty Ltd. All Rights Reserved.